Loading
companiesCompany
Artios Pharma
Artios Pharma is a Cambridge, UK biotechnology company that leads two cancer trials in OnCo, testing its DNA damage response inhibitors ART0380 (ATR) and ART6043 (DNA polymerase theta) in advanced solid tumours.
Also called: Artios Pharma LtdArtios Pharma LimitedArtios
Overview
Artios Pharma Limited is a company based in Cambridge, United Kingdom (Wikidata Q140045444, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. It leads two phase 1/2a trials recorded in OnCo: NCT04657068, the ATR kinase inhibitor ART0380 alone and in combination (with gemcitabine, irinotecan or FOLFIRI) in advanced or metastatic solid tumours including ovarian, endometrial, colorectal and pancreatic cancer, and NCT05898399 (POLKA), the DNA polymerase theta inhibitor ART6043 alone and with olaparib in advanced solid tumours. Both compounds are its own, which is the basis for the biotech type.
Similar pages
- CompanyImmunovaccine (IMV)
Shares Ovarian cancer and the tag wave5-sponsor.
- CompanyCriterium
Shares Colorectal cancer and the tag wave5-sponsor.
- TargetPOLQ
Shares DNA damage response & homologous recombination, Endometrial cancer, Ovarian cancer, Colorectal cancer.
- TechnologyATR and CHK1 inhibitors
Shares ATR, Ovarian cancer.
- PersonAlan D. D'Andrea
Shares ATR, Ovarian cancer.
- PairingPlatinum chemotherapy in HRD tumours
Shares DNA damage response & homologous recombination, Ovarian cancer.
- TermEnabling characteristic: genome instability and mutation
- TechnologyPARP PET
Shares DNA damage response & homologous recombination, Ovarian cancer.